Shots: The two P-III PRONTO-T1D & PRONTO-T2D studies result involves assessing of Ultra Rapid Lispro (URLi) vs Humalog (insulin lispro), both in combination with insulin glargine/degludec in 1,222 & 673 […]readmore
Tags : URLi
Latest Posts
Categories
Related Topics
AbbVie
Acceptance
Acquire
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Boehringer Ingelheim
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Lilly
Merck
Novartis
P-III
patients
Pfizer
receives
Regeneron
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
Treat
Treatment
US